Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic

Executive Summary

Despite its stock price falling 48% 24 hours after the shuttering of lead candidate revusiran, Alnylam is encouraged by analyst reports indicating the failure does not read through to its overall pipeline. The biotech reaffirmed its timeline for its second Phase III candidate patisiran.

Advertisement

Related Content

APOLLO Success Clears Alnylam For Lift-Off
Alnylam Hopes To Resume Fitusiran Dosing Quickly, Despite Unclear Cause Of Trial Death
Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints
Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings
RNA Therapeutics Near A Tipping Point, Says Silence’s CEO
From Solanezumab To Solithromycin: What To Watch For In Q4
Alnylam Ends Revusiran In Phase III, But Was Failure Due To Safety Or Efficacy?
Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option
Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work
Alnylam, Medicines Company PCSK9 Drug Has Quarterly Dose Potential

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097437

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel